Comparative Pharmacology
Head-to-head clinical analysis: RAPLON versus SERPANRAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAPLON versus SERPANRAY.
RAPLON vs SERPANRAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.
Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.
0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.
1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours in end-stage renal disease).
Terminal elimination half-life is approximately 62 hours following oral administration, allowing for once-daily dosing.
Primarily renal excretion of unchanged drug (approximately 80-90% of administered dose within 24 hours); minor biliary/fecal elimination (less than 10%).
Primarily hepatic metabolism via CYP1A2 and CYP3A4, with 18% excreted unchanged in urine and 26% in feces as metabolites.
Category C
Category C
Antihypertensive
Antihypertensive